Results 261 to 270 of about 8,564,356 (290)
Some of the next articles are maybe not open access.
Proteasome Inhibition Reduces Donor-Specific Antibody Levels
Transplantation Proceedings, 2009Current antibody-mediated rejection (AMR) therapies (intravenous immunoglobulin, apheresis, rituximab, polyclonal antibodies) do not target the primary antibody producing B cells, that is, the plasma cell. We report the preliminary results from the first clinical experience with plasma cell targeted therapy with bortezomib.
M J, Everly +14 more
openaire +2 more sources
Donor-Specific HLA Antibodies as Biomarkers of Transplant Rejection
Clinics in Laboratory Medicine, 2019This article reviews the current evidence to classify donor-specific antibodies (DSAs) using Food and Drug Administration-National Institutes of Health Biomarkers, EndpointS, and other Tools (BEST) resource terms as diagnostic, prognostic, predictive, monitoring, and risk biomarkers for graft rejection. The emphasis is on DSA characteristics, including
openaire +2 more sources
DONOR-SPECIFIC TRANSFUSION AND ANTIBODY RESPONSE
The Lancet, 1987M A, McMillan +4 more
openaire +2 more sources
Antibody–Drug Conjugates: Smart Chemotherapy Delivery Across Tumor Histologies
Ca-A Cancer Journal for Clinicians, 2022Shanu Modi +2 more
exaly
Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates
Ca-A Cancer Journal for Clinicians, 2006David M Goldenberg +2 more
exaly
New Developments in Monoclonal Antibodies for Cancer Detection Andtherapy
Ca-A Cancer Journal for Clinicians, 1994David M Goldenberg
exaly
Antibodies to Hepatitis C Virus in French Blood Donors.
Lancet, The, 1989C Janot, A M Courouce, A M Courouce
exaly